Cardiovascular Diseases

Function-Guided Complete Revascularization Improves Outcomes in STEMI

In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, complete coronary revascularization guided by functional coronary angiography significantly reduced both major cardiovascular events and key safety events compared with conventional angiography-guided treatment. In this international randomized trial, 1,823 patients whose culprit lesion had been successfully treated were assigned to function-guided or conventional angiography-guided complete revascularization. The primary composite outcome of death from any cause, myocardial infarction, cerebrovascular events, or ischemia-driven revascularization occurred in 8.9% of the function-guided group versus 13.7% of the angiography-guided group at a median follow-up of 17.9 months (hazard ratio [HR], 0.62). The primary safety outcome, a composite of contrast-associated acute kidney injury or major bleeding, also occurred less frequently with functional guidance (4.6% vs. 7.1%; HR, 0.63). These findings indicate that, among patients with STEMI and multivessel disease, using functional coronary angiography to guide complete revascularization provides better clinical outcomes than relying on conventional angiography alone. Source: https://www.nejm.org/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.